CASP3 and cancer: Here, in this model we found that Rimonabant was able to control cancer stemness, through activation of caspase 3, and then induction of cell death, in both differentiated tumor cells (characterized by Wnt-low activity) and in CSCs (defined as Wnt-high active cells).